BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 2115904)

  • 1. Selection of MDT strategies through epidemiometric modeling.
    Lechat MF; Declercq EE; Misson CB; Vellut CM
    Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):296-301. PubMed ID: 2115904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
    Jing Z; Zhang R; Zhou D; Chen J
    Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug therapy in leprosy can prevent relapse--a retrospective study.
    Biswas S; Mondal KK
    Indian J Lepr; 2002; 74(4):313-8. PubMed ID: 12624979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
    Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
    Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M; Berhe D
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse rates in patients treated with dapsone monotherapy and combinations of dapsone and thiambutosine, thiacetazone, isoniazid and streptomycin in the pre-MDT era.
    Smith TC; Richardus JH
    Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):353-8. PubMed ID: 7525795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The contribution of "cure by dapsone monotherapy' to the reduction of prevalence of leprosy in the State of Orissa, India, 1983-1993.
    Patnaik PK; McDougall AC
    Indian J Lepr; 1996; 68(3):223-6. PubMed ID: 8889607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three years assessment of multidrug therapy in multibacillary leprosy cases.
    Ganapati R; Revankar CR; Pai RR
    Indian J Lepr; 1987; 59(1):44-9. PubMed ID: 3611860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The frequency of the appearance of perforating foot ulcers in patients with Hansen's disease as a function of treatment with disulone alone or with polychemotherapy].
    Mane I; Grauwin MY; Cartel JL
    Acta Leprol; 1995; 9(3):127-31. PubMed ID: 7631583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed duration MDT in paucibacillary leprosy (classical and modified).
    Nadkarni NJ; Grugni A; Kini MS
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):25-8. PubMed ID: 8326177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in leprosy over fifty years in Gudiyatham Taluk, Vellore, Tamil Nadu.
    Norman G; Raja Samuel Bhushanam JD; Samuel P
    Indian J Lepr; 2006; 78(2):167-85. PubMed ID: 16927851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Multi-drug therapy trials for leprosy in Senegal: first observations relative to liver tolerance of multibacillary patients. Therapeutic consequences].
    Millan J; Roux G; Loko S; Naudin JC; Boucher P; Bodian M; Camara M; Moreira-Diop T; Grosset J
    Acta Leprol; 1986; 4(4):427-44. PubMed ID: 3296613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-duration multidrug therapy in multibacillary leprosy.
    Li HY; Hu LF; Wu PW; Luo JS; Liu XM
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):230-7. PubMed ID: 9251596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological shift in leprosy in a rural district of central India following introduction of multi-drug therapy (April 1986 to March 1992 and April 1992 to March 2002).
    Pandey A; Uddin MJ; Patel R
    Lepr Rev; 2005 Jun; 76(2):112-8. PubMed ID: 16038244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical analysis of multibacillary leprosy patients after 1-year fixed World Health Organization recommended multidrug therapy at Yangon General Hospital, Myanmar.
    Kyaw K; Tsoh TM; Swe SY; Nagaoka Y; Takezaki S; Suzuki K; Ishii N
    J Dermatol; 2008 May; 35(5):264-9. PubMed ID: 18477225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug therapy in leprosy.
    Manglani PR; Arif MA
    J Indian Med Assoc; 2006 Dec; 104(12):686-8. PubMed ID: 17474286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
    Chen XS; Li WZ; Jiang C; Ye GY
    Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.